Vestronidase Alfa (Mepsevii)

Vestronidase alfa is a recombinant enzyme-replacement drug for mucopolysaccharidosis type VII (MPS VII, or Sly syndrome), one of the rarest diseases treated by any drug on this site — an estimated 200 or fewer people are known to have it worldwide. Approved in 2017 as the first treatment for MPS VII anywhere, it was developed by Ultragenyx rather than the BioMarin that makes every other MPS enzyme drug covered on this site, and its pivotal trial used an unusual "blind start" design built specifically to let every one of its handful of eligible patients eventually receive the real drug — a genuine methodological adaptation to running a randomized trial in a disease with only a few hundred patients on Earth.

The rarest MPS disease this site covers

Mucopolysaccharidosis type VII (MPS VII, or Sly syndrome) is a rare inherited disorder caused by deficient activity of beta-glucuronidase, an enzyme that breaks down several glycosaminoglycans at once — dermatan sulfate, heparan sulfate and chondroitin sulfate — rather than just one or two, as in the MPS I, II, IVA and VI diseases covered elsewhere on this site. Estimates put the global patient population at roughly 200 or fewer known cases, making MPS VII genuinely rarer than every other mucopolysaccharidosis this site has covered. Its clinical spectrum is unusually wide even by rare-disease standards: the most severe form presents before birth as non-immune hydrops fetalis, a buildup of fluid in the fetus that is fatal in a meaningful share of cases, while more attenuated forms allow survival into adulthood with coarse facial features, corneal clouding, hepatosplenomegaly, skeletal disease, and — in some but not all patients — cognitive impairment. Notably, having hydrops fetalis in utero does not reliably predict how severe a surviving child's later disease course will be. Before 2017, no disease-specific drug existed for MPS VII. Ultragenyx Pharmaceutical — a different company from BioMarin, which developed every other enzyme-replacement drug covered on this site's MPS pages — developed recombinant human beta-glucuronidase (vestronidase alfa, internally UX003), and the FDA approved it on 15 November 2017 under the brand name Mepsevii, the first treatment for MPS VII approved anywhere.

An unusual trial design for a disease too rare for a normal one

With perhaps only a few hundred diagnosed patients worldwide and a small fraction of those eligible and willing to enroll, Ultragenyx could not run a conventional, adequately powered, parallel-group placebo-controlled trial the way BioMarin had for laronidase, idursulfase, elosulfase alfa or galsulfase. Instead, the pivotal study, UX003-CL301, used a "blind start" design: all 12 enrolled patients, aged 8 to 25, eventually received vestronidase alfa 4 mg/kg by IV infusion every two weeks, but each was randomly assigned to one of four groups that started active treatment at a different pre-specified time — some immediately, others only after a placebo-controlled run-in period of several weeks. Every patient still had a genuine period of blinded, placebo-controlled comparison built into the design, but no patient was left on placebo for the length of the whole study, an ethically and practically important adaptation for a disease this rare and this severe (Harmatz P, Whitley CB, Waber L, Boyer S, Rojas-Caro S, Turbeville S, "A novel Blind Start study design to investigate vestronidase alfa for mucopolysaccharidosis VII, an ultra-rare genetic disease," Mol Genet Metab 2018;123(4):488-494, PMID 29478819).¹

A biomarker that hit its mark, and a clinical index that narrowly missed

The trial's primary endpoint was reduction in urinary glycosaminoglycan excretion, a validated biomarker of disease burden used across this site's other MPS enzyme pages: after 24 weeks of active treatment, dermatan sulfate fell a mean 64.8% (P<.0001), a clear, statistically significant result. A separate, purpose-built secondary tool — the Multi-Domain Responder Index (MDRI), which scores clinically meaningful improvement across six different disease domains such as pulmonary function, walking endurance, fine motor skills and vision — found that most evaluable patients improved in at least one domain, with an overall mean MDRI change of +0.5 at week 24, but that result narrowly missed conventional statistical significance (P=.0527).¹ The FDA approved Mepsevii based on the totality of that evidence — a clearly significant biomarker result plus broadly, if not statistically definitively, favorable clinical-domain evidence — rather than treating the MDRI's near-miss as disqualifying on its own; the label itself notes that the drug's effect on MPS VII's central nervous system manifestations specifically has not been established. This is a genuinely similar pattern to cipaglucosidase alfa's own pivotal trial elsewhere on this site, where a missed primary statistical threshold didn't block approval once the surrounding evidence was considered as a whole — a reminder that FDA approval reflects a judgment about the totality of the evidence, not a single endpoint clearing a single line.

Current status

Mepsevii remains FDA-approved and currently marketed by Ultragenyx, and remains the only FDA-approved disease-specific treatment for MPS VII. Given how few patients have the disease, its commercial footprint is necessarily small even by this site's rare-disease standards: Ultragenyx reported $37 million in total Mepsevii revenue for all of 2025, and $7 million and $10 million respectively in the first and second quarters of 2026 — a genuinely tiny drug population reflected directly in genuinely tiny (if steady) revenue, a useful contrast to the far larger patient populations and revenues behind BioMarin's Vimizim and Naglazyme. No FDA-approved generic, biosimilar or competing disease-specific therapy for MPS VII exists as of 2026.